Comparison
Coenzyme Q10 vs Noopept
Side-by-side of Coenzyme Q10 and Noopept. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Coenzyme Q10
CoQ10 supplement guide: 100 to 300 mg/day dosing, ubiquinol vs ubiquinone absorption, Q-SYMBIO heart failure data, statin myalgia evidence.
Noopept
Noopept cognitive enhancer profile: 10 to 30 mg dosage, dipeptide nootropic mechanism, memory effects, and how it compares to piracetam.
Effects at a glance
Coenzyme Q10
- •Q-SYMBIO trial showed 43% reduction in major cardiovascular events at 300 mg/day in heart failure
- •Reduces statin-induced myalgia in some patients at 100-200 mg/day per Banach 2014 meta-analysis
- •Migraine prophylaxis at 300 mg/day daily; AHS lists at Level B for prevention
- •Ubiquinol absorbs 2-3x better than ubiquinone in adults over 60
- •Plasma CoQ10 falls 15-40% with chronic statin therapy
- •Small blood pressure reduction (3-5 mmHg systolic) at 100-200 mg/day
Noopept
- •Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
- •Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
- •Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
- •Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
- •Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
- •Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014
Side-by-side
| Attribute | Coenzyme Q10 | Noopept |
|---|---|---|
| Category | supplement | nootropic |
| Also known as | CoQ10, ubiquinone, ubiquinol, Q10 | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam |
| Half-life (hr) ↗ | 34 | 0.7 |
| Typical dose (mg) ↗ | 200 | 20 |
| Dosing frequency | 1 to 3 times daily with a fat-containing meal | 2 to 3 times daily, last dose before mid-afternoon |
| Routes | oral | oral, sublingual |
| Onset (hr) | 6 | 0.5 |
| Peak (hr) | 720 | 1 |
| Molecular weight | 863.36 | 318.37 |
| Molecular formula | C59H90O4 | C17H22N2O4 |
| Mechanism | Mobile electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain. Ubiquinol form acts as a lipid-soluble antioxidant in cell membranes and regenerates oxidized vitamin E. | Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects. |
| Legal status | Dietary supplement (most jurisdictions); prescription cardiac medication in Japan | Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies |
| WADA status | allowed | unknown |
| DEA / Rx | Not scheduled | Not scheduled in the US |
| Pregnancy | Limited safety data; precautionary use at standard doses | Not recommended |
| CAS | 303-98-0 | 157115-85-0 |
| PubChem CID | 5281915 | 183503 |
| Wikidata | Q140453 | Q4321022 |
Safety profile
Coenzyme Q10
Common side effects
- mild GI upset (rare)
- headache (rare)
- insomnia at very high doses
Contraindications
- active warfarin therapy without monitoring (modest interaction with INR)
Interactions
- warfarin: structural similarity to vitamin K may modestly reduce warfarin efficacy; monitor INR(moderate)
- antihypertensives: additive blood pressure-lowering at high doses(minor)
- statins: statins reduce CoQ10 synthesis; CoQ10 supplementation does not affect statin efficacy(minor)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Noopept
Common side effects
- headache
- irritability
- sleep disturbance with late-day dosing
- occasional blood pressure elevation
Contraindications
- pregnancy
- lactation
- pediatric use
- severe hepatic impairment
- severe renal impairment
Interactions
- memantine and other glutamatergic agents: theoretical AMPA-pathway interaction(minor)
- antidepressants: theoretical effect via BDNF axis, undocumented(minor)
- antihypertensives: occasional blood pressure elevation may require monitoring(minor)
Which Should You Take?
Coenzyme Q10 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Noopept is the right call when one of the conditionals below applies.
- → If your priority is cardiovascular health, pick Coenzyme Q10.
- → If your priority is healthspan extension, pick Coenzyme Q10.
- → If your priority is focus or working memory, pick Noopept.
- → If your priority is memory, pick Noopept.
Edge case: If you want to avoid controlled substance, Coenzyme Q10 is the more accessible choice.
Default choice: Coenzyme Q10. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Noopept only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Coenzyme Q10 and Noopept?
Coenzyme Q10 and Noopept differ in category (supplement vs nootropic), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Coenzyme Q10 or Noopept?
Coenzyme Q10 half-life is 34 hours; Noopept half-life is 0.7 hours.
Can you stack Coenzyme Q10 with Noopept?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper